Taken together, as a new CDK4/6 and PI3K/AKT multi-kinase inhibitor, aminoquinol is a potential drug for HCC treatment alone or in combination with 5-Fu, sorafenib and potentially other targeted anti-cancer drugs. This evidence concerns the gene CDK4 and hepatocellular carcinoma.